1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
Lysosomal Disease Treatments: Technologies and Global Markets

Lysosomal Disease Treatments: Technologies and Global Markets

  • September 2018
  • 118 pages
  • ID: 5564061
  • Format: PDF
  • By BCC Research

Summary

Table of Contents

Report Scope:
The lysosomal storage disease treatment market has been divided by type of indication into: Gaucher’s Diseases, Fabry Diseases, Pompe’s Syndrome, Mucopolysaccharidosis and more.Mucopolysaccharidosis is further segmented into Hunter syndrome, Hurlers Syndrome and Moriquo syndrome.

The market is also segmented by routing of administration into IV and oral.The market has been divided into hospitals, clinics and other facilities into end users by type of treatment into enzyme replacement therapy and substrate reduction therapy.

The market has been segmented into North America, Europe, Asia-Pacific and RoW.

Report Includes:
- 37 data tables and 25 additional tables
- An overview of the global market for lysosomal disease treatments
- Analyses of global market trends, with data from 2017, estimates for 2018 and projections of compound annual growth rates (CAGRs) through 2023
- Segmentation of the global market by cancer therapy indiscation, treatment type, route of administration, end-use, application and geographical region
- Information on current regulatory environment, and a trend analysis of recent government policies and regulations for lysosomal disease treatments
- Assessment of lysosomal storage diseases by the accumulated substrate and the profitability of focusing on ultra-orphan diseases
- Profiles of major players in the industry, including Astellas Pharma, Astrazeneca, Eli Lilly and Co., Merck & Co., Inc., and Novo Nordisk A/S

Summary
Lysosomal storage diseases are a rare group of genetic disorders that resulted from the malfunctioning or lack of lysosomal enzymes.Tay-Sachs disease was the first lysosomal storage disorder (LSD).

It was described in 1881 and was followed by Gaucher disease in 1882.The lysosomal storage diseases (LSD) are a group of 50 diseases that are characterized by accumulation of waste product in the lysosomes.

They are rare, inborn defects and have a combined incidence rate of 1 in 1,500 to 7,000 live births. In lysosomal storage diseases there is deficiency of 1 or more of themany catabolic enzymes that are located within the lysosome. Many of the diseases known today were described even before the
discovery of lysosomes. The last decade has witnessed major advances in our understanding of the clinical, biochemical and genetical aspects of lysosomal storage diseases.

The major drivers influencing the market are orphan drug status; this is a major driver of the market.Increasing awareness, rising focus by pharmaceutical companies and early diagnosis as well as newborn screening are the other drivers.

The market also faces a few restraints that include expensive drugs, change in payer policies, lack of proper training and knowledge, nature of disease and concerns in diagnosis. Restraints are overcome by the drugs that aid in improving the lifespan and quality of life for the patients.

U.S. is the major market for lysosomal storage disease treatment. It was the first country to implement orphan drug status and to provide many incentives for orphan drugs for treating rare diseases. Europe is the second-largest market; it also stands by the Orphan Drug Act. Asia-Pacific is showing the highest growth rate during the forecasted period. In China and India, the market is limited due to the high prices of the drugs.

The lysosomal storage diseases market is a subset of the larger orphan drugs market and is impacted by any change in regulation and policy on orphan drugs.There is an increasing focus on LSD as there are efficient diagnostic systems to detect greater numbers of patients.

The market for Lysosomal storage diseases is estimated to reach a value of nearly REDACTED in 2018 and is expected to grow at a compound annual growth rate (CAGR) of REDACTED to nearly REDACTED by 2023.Themarket for Lysosomalstorage diseases is a concentrated market with many large players present in the market.

Major players in themarket are Sanofi, Pfizer, Shi re and others.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
10% Off

($4950)

  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Atherosclerosis - Pipeline Review, H2 2019

Atherosclerosis - Pipeline Review, H2 2019

  • $ 2000
  • November 2019

Atherosclerosis - Pipeline Review, H2 2019SummaryThe latest Pharmaceutical and Healthcare disease pipeline guide Atherosclerosis - Pipeline Review, H2 2019, provides an overview of the Atherosclerosis ...

Hyperuricemia - Pipeline Review, H2 2019

Hyperuricemia - Pipeline Review, H2 2019

  • $ 2000
  • November 2019

Hyperuricemia - Pipeline Review, H2 2019SummaryThis latest Pharmaceutical and Healthcare disease pipeline guide Hyperuricemia - Pipeline Review, H2 2019, provides an overview of the Hyperuricemia (Metabolic ...

Rhinovirus Infections - Pipeline Review, H2 2019

Rhinovirus Infections - Pipeline Review, H2 2019

  • $ 2000
  • November 2019

Rhinovirus Infections - Pipeline Review, H2 2019SummaryThe latest Pharmaceutical and Healthcare disease pipeline guide Rhinovirus Infections - Pipeline Review, H2 2019, provides an overview of the Rhinovirus ...


ref:plp2018

Reportlinker.com © Copyright 2019. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on